With IPO Off The Table, Argos Takes $25 Million From VCs
This article was originally published in The Pink Sheet Daily
Executive Summary
The cancer immunotherapy developer withdrew its IPO registration last month, turning instead to insider investors as it prepares for a pivotal Phase III trial on a dendritic cell treatment.